NCT07305311

Brief Summary

The prospective study aims to characterize the network-specific modulatory effects of piriform cortex stimulation in patients undergoing stereotactic EEG for drug-resistant epilepsy. Using multimodal data, it seeks to link stimulation-evoked electrophysiological responses across brain networks with clinical outcomes, to inform targeted neuromodulation therapies.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable

Timeline
18mo left

Started Dec 2025

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress22%
Dec 2025Nov 2027

First Submitted

Initial submission to the registry

December 2, 2025

Completed
6 days until next milestone

Study Start

First participant enrolled

December 8, 2025

Completed
18 days until next milestone

First Posted

Study publicly available on registry

December 26, 2025

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 8, 2027

Expected
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 8, 2027

Last Updated

December 26, 2025

Status Verified

December 1, 2025

Enrollment Period

1.1 years

First QC Date

December 2, 2025

Last Update Submit

December 12, 2025

Conditions

Keywords

SEEGPiriform cortexElectrical stimulationElectrophysiology

Outcome Measures

Primary Outcomes (1)

  • Seizure Discharge Suppression Rate

    Quantified as the percentage reduction in the frequency of spikes and interictal epileptiform discharges (IEDs) during active stimulation compared to the baseline period.

    72 hours

Secondary Outcomes (7)

  • Single-Pulse Stimulation Amplitude:

    72 hours

  • N1 Component Amplitude and Latency:

    72 hours

  • Spatial Distribution of Activation

    72 hours

  • Effective Connectivity Change:

    72 hours

  • Phase-Amplitude Coupling Index

    72 hours

  • +2 more secondary outcomes

Study Arms (1)

SEEG recordings and SPES effects

EXPERIMENTAL

This arm encompasses patients with drug-resistant focal epilepsy who underwent intracranial monitoring via stereotactically implanted depth electrodes (SEEG) as part of their standard presurgical evaluation. During the monitoring period, these patients additionally underwent systematic Single-Pulse Electrical Stimulation (SPES) mapping. SPES was administered according to a standardized clinical protocol, involving the delivery of single, low-intensity electrical pulses to selected electrode contacts-including those located within or adjacent to the piriform cortex-while recording the evoked electrophysiological responses across the implanted SEEG network. The data collected in this arm include continuous intracranial EEG recordings, precise stimulation parameters (location, intensity), and the corresponding electrophysiological responses used to characterize cortico-cortical evoked potentials and network connectivity.

Device: SEEG recordings and SPES

Interventions

The intervention involves single-pulse electrical stimulation (SPES) applied during stereotactic electroencephalography (SEEG) monitoring. Low-intensity, standardized electrical pulses are delivered to targeted contacts within or near the piriform cortex via implanted depth electrodes, while simultaneous full-bandwidth SEEG recordings capture network-wide electrophysiological responses, allowing characterization of stimulation-evoked brain network activation and modulation patterns.

SEEG recordings and SPES effects

Eligibility Criteria

Age14 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • The patients were diagnosed with drug-resistant epilepsy.
  • The patients underwent stereoelectroencephalography (SEEG) implantation for pre-surgical evaluation of epilepsy, with at least one electrode target reaching the piriform cortex

You may not qualify if:

  • Subjects that experience surgical complications during the implant procedure will be excluded from the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Xuanwu Hospital

Beijing, Beijing Municipality, 100053, China

Location

MeSH Terms

Conditions

Drug Resistant Epilepsy

Condition Hierarchy (Ancestors)

EpilepsyBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Study Officials

  • Liankun Ren

    Xuanwu Hospital, Beijing

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Liankun Ren, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
professor

Study Record Dates

First Submitted

December 2, 2025

First Posted

December 26, 2025

Study Start

December 8, 2025

Primary Completion (Estimated)

January 8, 2027

Study Completion (Estimated)

November 8, 2027

Last Updated

December 26, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share

Locations